Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis

被引:453
作者
Zheng, Caifang [1 ]
Shao, Weihao [1 ]
Chen, Xiaorui [1 ]
Zhang, Bowen [1 ]
Wang, Gaili [1 ]
Zhang, Weidong [1 ]
机构
[1] Zhengzhou Univ, Sch Publ Hlth, Dept Epidemiol, Zhengzhou 450001, Henan, Peoples R China
关键词
COVID-19; SARS-CoV-2; Vaccine; Effectiveness; Real-world; SEASONAL INFLUENZA; VACCINATION; IMPACT;
D O I
10.1016/j.ijid.2021.11.009
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against concerned outcomes in real-world settings. Methods: Studies reporting COVID-19 VE from August 6, 2020 to October 6, 2021 were included. The summary VE (with 95% confidence intervals (95% CI)) against disease related to COVID-19 was estimated. The results were presented in forest plots. Predefined subgroup analyses and sensitivity analyses were also performed. Results: A total of 51 records were included in this meta-analysis. In fully vaccinated populations, the VE against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19-related hospitalization, admission to the intensive care unit, and death was 89.1% (95% CI 85.6-92.6%), 97.2% (95% CI 96.1-98.3%), 97.4% (95% CI 96.0-98.8%), and 99.0% (95% CI 98.5-99.6%), respectively. The VE against infection in the general population aged >16 years, the elderly, and healthcare workers was 86.1% (95% CI 77.8-94.4%), 83.8% (95% CI 77.1-90.6%), and 95.3% (95% CI 92.0-98.6%), respectively. For those fully vaccinated against infection, the observed effectiveness of the Pfizer-BioNTech vaccine was 91.2% and of the Moderna vaccine was 98.1%, while the effectiveness of the CoronaVac vaccine was found to be 65.7%. Conclusions: The COVID-19 vaccines are highly protective against SARS-CoV-2-related diseases in real world settings.(c) 2021 Zhengzhou University. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:252 / 260
页数:9
相关论文
共 42 条
[1]   Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants [J].
Abu-Raddad, Laith J. ;
Chemaitelly, Hiam ;
Butt, Adeel A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) :187-189
[2]   Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine [J].
Baden, Lindsey R. ;
El Sahly, Hana M. ;
Essink, Brandon ;
Kotloff, Karen ;
Frey, Sharon ;
Novak, Rick ;
Diemert, David ;
Spector, Stephen A. ;
Rouphael, Nadine ;
Creech, C. Buddy ;
McGettigan, John ;
Khetan, Shishir ;
Segall, Nathan ;
Solis, Joel ;
Brosz, Adam ;
Fierro, Carlos ;
Schwartz, Howard ;
Neuzil, Kathleen ;
Corey, Larry ;
Gilbert, Peter ;
Janes, Holly ;
Follmann, Dean ;
Marovich, Mary ;
Mascola, John ;
Polakowski, Laura ;
Ledgerwood, Julie ;
Graham, Barney S. ;
Bennett, Hamilton ;
Pajon, Rolando ;
Knightly, Conor ;
Leav, Brett ;
Deng, Weiping ;
Zhou, Honghong ;
Han, Shu ;
Ivarsson, Melanie ;
Miller, Jacqueline ;
Zaks, Tal .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (05) :403-416
[3]   Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study [J].
Bernal, Jamie Lopez ;
Andrews, Nick ;
Gower, Charlotte ;
Robertson, Chris ;
Stowe, Julia ;
Tessier, Elise ;
Simmons, Ruth ;
Cottrell, Simon ;
Roberts, Richard ;
O'Doherty, Mark ;
Brown, Kevin ;
Cameron, Claire ;
Stockton, Diane ;
McMenamin, Jim ;
Ramsay, Mary .
BMJ-BRITISH MEDICAL JOURNAL, 2021, 373
[4]   Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021 [J].
Britton, Amadea ;
Slifka, Kara M. Jacobs ;
Edens, Chris ;
Nanduri, Srinivas Acharya ;
Bart, Stephen M. ;
Shang, Nong ;
Harizaj, Adora ;
Armstrong, Jillian ;
Xu, Kerui ;
Ehrlich, Hanna Y. ;
Soda, Elizabeth ;
Derado, Gordana ;
Verani, Jennifer R. ;
Schrag, Stephanie J. ;
Jernigan, John A. ;
Leung, Vivian H. ;
Parikh, Sunil .
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2021, 70 (11) :396-401
[5]   BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel [J].
Brosh-Nissimov, Tal ;
Orenbuch-Harroch, Efrat ;
Chowers, Michal ;
Elbaz, Meital ;
Nesher, Lior ;
Stein, Michal ;
Maor, Yasmin ;
Cohen, Regev ;
Hussein, Khetam ;
Weinberger, Miriam ;
Zimhony, Oren ;
Chazan, Bibiana ;
Najjar, Ronza ;
Zayyad, Hiba ;
Rahav, Galia ;
Wiener-Well, Yonit .
CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (11) :1652-1657
[6]  
CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI [10.15585/mmwr.mm6912e2, 10.15585/mmwr.mm6915e4]
[7]   Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization [J].
Chodick, Gabriel ;
Tene, Lilac ;
Patalon, Tal ;
Gazit, Sivan ;
Ben Tov, Amir ;
Cohen, Dani ;
Muhsen, Khitam .
JAMA NETWORK OPEN, 2021, 4 (06) :E2115985
[8]   Vaccination in the elderly: The challenge of immune changes with aging [J].
Ciabattini, Annalisa ;
Nardini, Christine ;
Santoro, Francesco ;
Garagnani, Paolo ;
Franceschi, Claudio ;
Medaglini, Donata .
SEMINARS IN IMMUNOLOGY, 2018, 40 (0C) :83-94
[9]   BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting [J].
Dagan, Noa ;
Barda, Noam ;
Kepten, Eldad ;
Miron, Oren ;
Perchik, Shay ;
Katz, Mark A. ;
Hernan, Miguel A. ;
Lipsitch, Marc ;
Reis, Ben ;
Balicer, Ran D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) :1412-1423
[10]  
Deplanque D., THERAPIES, V2021